World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
32626
World Ranking
15914
National Ranking
529

Research.com Recognitions

  • 2021 - Fellow of the Australian Academy of Health and Medical Science

Overview

Danny Rischin is a researcher affiliated with the Peter MacCallum Cancer Centre in Australia. Their work primarily focuses on oncology, with significant contributions in subfields such as otorhinolaryngology, epidemiology, pulmonary and respiratory medicine, and immunology.

Their research covers a range of topics, including:

  • Head and Neck Cancer Studies
  • Cancer Immunotherapy and Biomarkers
  • Nonmelanoma Skin Cancer Studies
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Lung Cancer Treatments and Mutations
  • Immunotherapy and Immune Responses

Danny Rischin has an extensive publication record in several high-profile venues, notably:

  • Journal of Clinical Oncology
  • International Journal of Radiation Oncology*Biology*Physics
  • Annals of Oncology
  • Oral Oncology
  • SKIN The Journal of Cutaneous Medicine

Significant papers featuring Rischin include:

  • "Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing," 2020, Journal for ImmunoTherapy of Cancer
  • "Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial," 2020, The Lancet Oncology
  • "Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study," 2022, Journal of Clinical Oncology
  • "Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma," 2022, New England Journal of Medicine
  • "Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial," 2023, The Lancet Oncology

Frequent collaborators with Rischin include:

  • Matthew G. Fury
  • Brett Hughes
  • Kevin J. Harrington
  • Mathias Bressel
  • Makoto Tahara

In 2021, Danny Rischin was recognized as a Fellow of the Australian Academy of Health and Medical Science.

Best Publications

  • Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

    Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura

  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

    Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières

  • PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma

    Michael R. Migden;Danny Rischin;Chrysalyne D. Schmults;Alexander Guminski

  • Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

    Danny Rischin;Richard J. Young;Richard Fisher;Stephen B. Fox

  • Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02

    Lester J. Peters;Brian O'Sullivan;Jordi Giralt;Thomas J. Fitzgerald

  • Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02

    Danny Rischin;Rodney J. Hicks;Richard Fisher;David Binns

  • Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer

    Michael P. Mac Manus;Rodney J. Hicks;Jane P. Matthews;Allan McKenzie

  • Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

    Joan Albanell;Federico Rojo;Steve Averbuch;Andrea Feyereislova

  • Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group

    Danny Rischin;Lester J. Peters;Brian O'Sullivan;Jordi Giralt

  • Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

    J. Simon W. Stewart;Ezra E.W. Cohen;Lisa Licitra;Carla M.L. Van Herpen

  • Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.

    Michael R Migden;Nikhil I Khushalani;Anne Lynn S Chang;Karl D Lewis

  • Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.

    Benjamin Solomon;Benjamin Solomon;Richard J Young;Danny Rischin

  • Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02)

    Danny Rischin;Lester Peters;Richard Fisher;Andrew Macann

  • Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

    S. N. Holden;S. G. Eckhardt;R. Basser;R. de Boer

  • F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment.

    Michael P. Mac Manus;Rodney J. Hicks;David L. Ball;Victor Kalff

  • Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer

    Sandro V. Porceddu;Elizabeth Jarmolowski;Elizabeth Jarmolowski;Rodney J. Hicks;Rob Ware

  • Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.

    Jeremy D. Shapiro;Michael J. Millward;Danny Rischin;Michael Michael

  • A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.

    Michael Friedlander;Kenneth C. Hancock;Danny Rischin;Mark J. Messing

  • The 'QUAD SHOT'--a phase II study of palliative radiotherapy for incurable head and neck cancer.

    June Corry;Lester J. Peters;Ieta D' Costa;Alvin D. Milner

  • Head and Neck Squamous Cell Carcinoma

    Richard J. Young;Danny Rischin;Richard Fisher;Grant A. McArthur

Frequent Co-Authors

Rodney J. Hicks
Rodney J. Hicks Peter MacCallum Cancer Centre
Benjamin Solomon
Benjamin Solomon Peter MacCallum Cancer Centre
Lester J. Peters
Lester J. Peters Peter MacCallum Cancer Centre
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
John R. Zalcberg
John R. Zalcberg Monash University
Michael A. Quinn
Michael A. Quinn International Gynaecological Cancer Society
Stephen B. Fox
Stephen B. Fox Peter MacCallum Cancer Centre
Lisa Licitra
Lisa Licitra University of Milan
Quynh-Thu Le
Quynh-Thu Le Stanford University
Alexander Dobrovic
Alexander Dobrovic University of Melbourne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens diverse opportunities beyond the traditional MD route. Many students consider alternative pathways and specialized online programs to advance their careers in healthcare.

Nursing professionals can expand their expertise through asn to fnp bridge programs, allowing a streamlined transition from Associate Degree in Nursing to Family Nurse Practitioner roles. For those looking to further nursing education without the hands-on clinical requirements, online rn to bsn programs no clinicals offer flexibility and convenience.

Healthcare management is another promising avenue. If you aspire to lead healthcare organizations, pursuing one of the best mha programs online, especially those accredited by CAHME, is a strong choice.

Additionally, an online degree nutrition can set the stage for careers in dietetics, wellness coaching, or public health. These varied pathways enable students to match their interests with high-demand healthcare fields, while enjoying the flexibility of online learning.

Best Scientists Citing Danny Rischin

Trending Scientists